Overview GSK1120212 Rollover Study Status: Terminated Trial end date: 2018-01-18 Target enrollment: Participant gender: Summary This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212. Phase: Phase 2 Details Lead Sponsor: GlaxoSmithKlineNovartis PharmaceuticalsTreatments: CarboplatinDocetaxelErlotinib HydrochlorideEverolimusGemcitabinePaclitaxelPemetrexedTrametinib